Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiary, Yuxi Walvax Biotechnology Co., Ltd., has obtained the "Biological Product Marketing Authorization" from the Egyptian Drug Authority (EDA) for its 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13). This approval grants the vaccine marketing authorization in Egypt.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments